What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce and provide Amgen's unaudited financial results for the third quarter and the first nine months of 2010, along with its financial position as of September 30, 2010. It directs investors to a press release for the detailed financial information.

What are 'non-GAAP financial measures' and why does Amgen use them?

Non-GAAP financial measures are financial metrics that exclude certain items that are reported under U.S. Generally Accepted Accounting Principles (GAAP). Amgen uses them to provide investors with supplementary information that management believes helps in analyzing the company's underlying business performance and facilitating comparisons between different reporting periods, by excluding items like stock option expensing, acquisition-related amortization, and certain tax adjustments.

What specific items are adjusted in Amgen's non-GAAP reporting?

Amgen adjusts for several items including the impact of expensing stock options, amortization of intangible assets from past acquisitions (like Avidia, Abgenix, and Immunex), non-cash interest expense related to convertible notes, income tax benefits from resolving transfer pricing issues, and net awards or accruals for legal settlements. The specific adjustments can vary slightly between periods.

Are the non-GAAP measures the primary way investors should evaluate Amgen's performance?

No, Amgen explicitly states that its non-GAAP financial measures are supplemental and not a substitute for, or superior to, measures prepared in accordance with GAAP. Investors should consider both GAAP and non-GAAP results, as well as other information provided in the company's filings, to form a complete understanding of Amgen's financial condition and performance.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 25, 2010, to report its unaudited financial results for the third quarter and the first nine months of 2010. The filing primarily directs investors to a press release (Exhibit 99.1) that details these results and provides non-GAAP financial measures. These non-GAAP measures are presented to offer investors a more insightful view of the company's operational performance by excluding certain items that management believes do not reflect the underlying business trends. The press release and the associated 8-K detail adjustments made to GAAP results. These adjustments include factors like stock option expensing, amortization of acquired intangible assets related to significant acquisitions (Avidia, Abgenix, Immunex), changes in accounting for convertible notes, income tax benefits/expenses from resolving transfer pricing issues, and legal settlements. Amgen emphasizes that these non-GAAP measures are supplemental and not a substitute for GAAP reporting, aiming to facilitate comparisons across periods by neutralizing the impact of these specific items.

Key Highlights

1Amgen announced its third quarter and nine-month 2010 financial results via an 8-K filing on October 25, 2010.
2The filing references an accompanying press release (Exhibit 99.1) containing the detailed financial results and analysis.
3Amgen presented both GAAP and non-GAAP financial measures to provide investors with a comprehensive view.
4Key adjustments to GAAP figures in non-GAAP reporting include stock option expensing, amortization of acquired intangibles (e.g., from Abgenix, Immunex), and effects of convertible note accounting.
5The company also adjusted for significant one-time or non-recurring items such as income tax benefits from transfer pricing resolutions and legal settlements.
6Amgen's management believes these non-GAAP adjustments offer supplemental information to facilitate better period-to-period comparisons.
7The report details specific adjustments for both the three and nine months ended September 30, 2010, and comparable periods in 2009.

AMGEN INC 8-K Report, Financial Results (Oct 25, 2010)

Summary

Key Highlights

Frequently Asked Questions